Miragen Therapeutics, Inc. announced that new interim results from its ongoing Phase 1 clinical trial of MRG-106 in patients with the mycosis fungoides form of cutaneous T-cell lymphoma (CTCL) will be presented at the 10th Annual T-cell Lymphoma Forum. The meeting is being held February 1-3, 2018 in La Jolla, CA. MRG-106 is an inhibitor of microRNA-155. In CTCL, as well as certain other blood cancers, microRNA-155 is present at abnormally high levels, and may play a role in the proliferation of blood and lymph cells. miRagen believes therapeutic inhibition of microRNA-155 may reduce aberrant cell proliferation and the tumor growth characteristic of certain types of cancer.